Cipla Health unveils Evexpert, women's feminine hygiene range

Chennai: Cipla Health Limited, the consumer healthcare subsidiary of Cipla, today expanded its portfolio with 'Evexpert',women's feminine hygiene range of products. EveX pertaims to set imagery of wise BFF with right expertise, enabling every woman to take care of herself and comes with a varied range of products like intimate wash, foot and elbow cream, underarm complete care cream and body care oil, a company release said. Feminine hygiene and discussions around it has been an age-old stigma. In current society, women and socially conditioned to stay reserved about their bodies hence they still prefer conversations around feminine hygiene and care behind closed doors. Furthermore, with lack of education around women's hygiene, UTI (Urinary Tract Infection) is still a looming concern for Indian women and ill-informed hygiene practices can trigger this menace.In fact, the feminine hygiene products market has seen an unprecedented growth and was valued at in 2020 and is expected to incline upwards at a CAGR of 16.87%. The Evexpert bouquet of products enables her to be the protagonist of her own story and is pointed towards helping her routinize feminine hygiene and care as an essential everyday practice. Of the 99 problems she battles, "she-care" shouldn't be one! Evexpert comes from the house of Cipla and is infused with the goodness of natural ingredients.

Read Also- Cipla gets CDSCO panel okay to manufacture, market Metformin, Sitagliptin FDC

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement.

Read Also - Cipla gets CDSCO panel nod to conduct Indian trials of Paxlovid